An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
1 Sorbonne Université, Faculté de Médecine, Service de Dermatologie et Allergologie, AP-HP, Hôpital Tenon, Paris, France.
2 Centres Régionaux de Pharmacovigilance Pitié et Saint-Antoine, Service de Pharmacologie Médicale, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France.
3 Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP.Sorbonne Université, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi), CIC-1901, Paris, France.
4 Département de Pharmacovigilance, Hôpital Universitaire de Rouen, Rouen, France.
5 Département de Pharmacologie Médicale et Toxicologie, Centre Régional de Pharmacovigilance et d'Information sur le Médicament, Hôpital Lapeyronie, CHU Lapeyronie, Montpellier, France.
1 Sorbonne Université, Faculté de Médecine, Service de Dermatologie et Allergologie, AP-HP, Hôpital Tenon, Paris, France.
2 Centres Régionaux de Pharmacovigilance Pitié et Saint-Antoine, Service de Pharmacologie Médicale, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France.
3 Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP.Sorbonne Université, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi), CIC-1901, Paris, France.
4 Département de Pharmacovigilance, Hôpital Universitaire de Rouen, Rouen, France.
5 Département de Pharmacologie Médicale et Toxicologie, Centre Régional de Pharmacovigilance et d'Information sur le Médicament, Hôpital Lapeyronie, CHU Lapeyronie, Montpellier, France.
This descriptive case series investigates the potential association between the use of proton pump inhibitors and drug-induced lupus erythematosus in cases reported in 2 large pharmacovigilance databases.
Conflict of Interest Disclosures: Dr Tubach reported payments from GSK, Novartis, and UCB to Dr Tubach’s institution for participation in scientific committees outside the submitted work. No other disclosures were reported.
References
Arnaud L, Mertz P, Gavand PE, et al. . Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database. Ann Rheum Dis. 2019;78(4):504-508. doi:10.1136/annrheumdis-2018-214598
-
DOI
-
PubMed
Kawka L, Mertz P, Chasset F, Lebrun-Vignes B, Salem JE, Arnaud L. Characterization of drug-induced cutaneous lupus: analysis of 1994 cases using the WHO pharmacovigilance database. Autoimmun Rev. 2021;20(1):102705. doi:10.1016/j.autrev.2020.102705
-
DOI
-
PubMed
Grönhagen CM, Fored CM, Linder M, Granath F, Nyberg F. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol. 2012;167(2):296-305. doi:10.1111/j.1365-2133.2012.10969.x
-
DOI
-
PubMed
Haugaard JH, Kofoed K, Gislason G, Dreyer L, Egeberg A. Association between drug use and subsequent diagnosis of lupus erythematosus. JAMA Dermatol. 2020;156(11):1199-1207. doi:10.1001/jamadermatol.2020.2786
-
DOI
-
PMC
-
PubMed
